Anumana
Founded Year
2021Stage
Series C | AliveTotal Raised
$127.4MValuation
$0000Last Raised
$95.4M | 6 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+48 points in the past 30 days
About Anumana
Anumana is an AI-driven health technology company focused on transforming cardiac care through advanced analysis of electrical signals from the heart. The company offers AI solutions that enable earlier diagnosis of cardiovascular diseases and improve clinical decision-making in electrophysiology. Anumana's products are designed for integration into clinical workflows, for healthcare providers in early disease detection and intervention and enhancing patient safety and outcomes. It was founded in 2021 and is based in Cambridge, Massachusetts.
Loading...
ESPs containing Anumana
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The electrocardiogram (ECG) diagnostics market focuses on the development and adoption of tech-enabled solutions designed to assist in the interpretation and analysis of electrocardiogram (ECG) data. ECG is a critical diagnostic tool for assessing the electrical activity of the heart, and tech applications in this market aim to improve the accuracy and efficiency of diagnosing cardiac conditions a…
Anumana named as Outperformer among 15 other companies, including Samsung, Apple, and Eko.
Loading...
Research containing Anumana
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Anumana in 3 CB Insights research briefs, most recently on Oct 20, 2025.
Oct 20, 2025 report
Digital Health 50: The most promising digital health startups of 2025
Expert Collections containing Anumana
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Anumana is included in 3 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Artificial Intelligence (AI)
20,628 items
Digital Health 50
50 items
Anumana Patents
Anumana has filed 21 patents.
The 3 most popular patent topics include:
- cardiac arrhythmia
- artificial neural networks
- diagrams
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/30/2024 | 4/1/2025 | Cardiac arrhythmia, Medical imaging, Parallel computing, Network topology, Wireless networking | Grant |
Application Date | 7/30/2024 |
|---|---|
Grant Date | 4/1/2025 |
Title | |
Related Topics | Cardiac arrhythmia, Medical imaging, Parallel computing, Network topology, Wireless networking |
Status | Grant |
Latest Anumana News
Jul 21, 2025
by Gus Iversen , Editor in Chief | July 21, 2025 Rating saved Royal Philips has introduced a new digital platform designed to streamline access to AI-based electrocardiogram (ECG) tools for cardiac care teams. The ECG AI Marketplace brings together offerings from multiple vendors into one integrated system for hospitals and health systems using Philips’ infrastructure. Anumana, a health tech firm focused on AI-powered cardiac diagnostics, is the first company to have a certified solution available through the platform. Its FDA-cleared algorithm for detecting low ejection fraction (LEF)—a key indicator of heart failure—is now available across Philips' ECG suite, including IntelliSpace ECG and its cardiograph systems. Ad Statistics Times Visited: 120 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits. The LEF algorithm uses data from standard 12-lead resting ECGs to identify signs of reduced heart function earlier in the care process. According to Anumana, the technology has been studied in over 150,000 patients and supported by close to 100 peer-reviewed publications. “We’re proud to be the flagship offering on the Philips ECG AI Marketplace,” said Simos Kedikoglou, MD, president and chief operating officer at Anumana. “Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance.” Philips said the Marketplace was created in response to growing demand from hospitals using multiple AI tools across different platforms. By consolidating these tools under one system, the platform aims to reduce the operational burden on hospital IT teams while supporting faster diagnosis and improved clinical decision-making. “Through the Philips ECG AI Marketplace, we’re building a more flexible and connected approach to innovation in cardiac care,” said Stefano Folli, business leader for ambulatory monitoring and diagnostics at Philips. The Netherlands-based company said the launch marks an ongoing effort to open its ECG ecosystem to external developers and AI solutions.
Anumana Frequently Asked Questions (FAQ)
When was Anumana founded?
Anumana was founded in 2021.
Where is Anumana's headquarters?
Anumana's headquarters is located at One Main Street, Cambridge.
What is Anumana's latest funding round?
Anumana's latest funding round is Series C.
How much did Anumana raise?
Anumana raised a total of $127.4M.
Who are the investors of Anumana?
Investors of Anumana include Mayo Clinic, NTT Venture Capital, Matrix Capital, Matrix Partners, Boston Scientific and 3 more.
Who are Anumana's competitors?
Competitors of Anumana include Powerful Medical and 2 more.
Loading...
Compare Anumana to Competitors
Idoven is a health technology company that focuses on detection and medicine in the cardiovascular domain. The company offers an artificial intelligence (AI)-powered platform that improves the speed, consistency, and accuracy of electrocardiogram (ECG) interpretation and works with existing ECG devices to support clinician decision-making and disease management. It was founded in 2018 and is based in Madrid, Spain.
Powerful Medical focuses on artificial intelligence (AI) driven healthcare solutions within the medical diagnostics sector. The company provides the PMcardio platform, which uses artificial intelligence to interpret 12-lead electrocardiograms (ECGs) for the diagnosis of cardiovascular diseases. PMcardio's technology aims to assist healthcare professionals by improving diagnostic capabilities and facilitating care coordination. It was founded in 2017 and is based in Bratislava, Slovakia (Slovak Republic).
Cardiomatics operates in the healthcare technology sector, focusing on ECG analysis. The company provides automated long-term ECG interpretation and arrhythmia diagnostics using a cloud-based platform for ECG signal analysis and reporting. Cardiomatics serves cardiac clinics and service providers. It was founded in 2017 and is based in Krakow, Poland.
Cardiolyse is a cloud-based platform that provides Electrocardiogram and heart rate variability (HRV) analytics for the healthcare sector. The company offers services including remote heart health monitoring, detection of heart conditions, and predictions of cardiovascular events using machine-learning algorithms. Cardiolyse serves healthcare providers, insurance companies, and individuals at risk for heart disorders. It was founded in 2015 and is based in Helsinki, Finland.
Ultromics operates within the medical technology industry and focuses on heart failure detection. The company offers diagnostic tools that analyze echocardiograms to identify conditions such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis, providing clinicians with reports to assist in clinical decisions. Ultromics serves healthcare providers, including hospitals and clinics, by integrating its technology into existing medical imaging workflows. It was founded in 2017 and is based in Oxford, England.
Abbott Cardiac Rhythm Management specializes in the development of medical devices and solutions for treating cardiovascular conditions. The company offers a range of products that assist in cardiac rhythm management, vascular health, and heart failure monitoring, designed to improve patient outcomes and support healthcare professionals. These products are primarily utilized within the healthcare sector, including hospitals, clinics, and by healthcare professionals specializing in cardiovascular care. It was founded in 2018 and is based in Abbott Park, Illinois.
Loading...